UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 30

Sortiert nach

Hepatitis C virus drug resistance–associated substitutions: State of the art summary

Hepatology (Baltimore, Md.), 2015-11, Vol.62 (5), p.1623-1632

2015

Volltextzugriff (PDF)

An Interferon-free Antiviral Regimen for HCV after Liver Transplantation

The New England journal of medicine, 2014-12, Vol.371 (25), p.2375-2382

2014

Volltextzugriff (PDF)

Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection

Journal of gastroenterology, 2018-04, Vol.53 (4), p.566-575

2018

Volltextzugriff (PDF)

Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis

Journal of gastroenterology, 2018-04, Vol.53 (4), p.557-565

2018

Volltextzugriff (PDF)

Randomized trial of interferon‐ and ribavirin‐free ombitasvir/paritaprevir/ritonavir in treatment‐experienced hepatitis C virus–infected patients

Hepatology (Baltimore, Md.), 2015-05, Vol.61 (5), p.1523-1532

2015

Volltextzugriff (PDF)

Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b–infected Japanese patients with or without cirrhosis

Hepatology (Baltimore, Md.), 2015-10, Vol.62 (4), p.1037-1046

2015

Volltextzugriff (PDF)

Mutations Conferring Resistance to a Potent Hepatitis C Virus Serine Protease Inhibitor In Vitro

Antimicrobial Agents and Chemotherapy, 2004-06, Vol.48 (6), p.2260-2266

2004

Volltextzugriff (PDF)

Ombitasvir/paritaprevir/ritonavir plus ribavirin for 24 weeks in patients with HCV GT4 and compensated cirrhosis (AGATE‐I Part II)

Health science reports, 2019-03, Vol.2 (3), p.e92-n/a

2019

Volltextzugriff (PDF)

Evolution of Resistant M414T Mutants among Hepatitis C Virus Replicon Cells Treated with Polymerase Inhibitor A-782759

Antimicrobial Agents and Chemotherapy, 2007-06, Vol.51 (6), p.1889-1896

2007

Volltextzugriff (PDF)

Activity of a Potent Hepatitis C Virus Polymerase Inhibitor in the Chimpanzee Model

Antimicrobial Agents and Chemotherapy, 2007-12, Vol.51 (12), p.4290-4296

2007

Volltextzugriff (PDF)

Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir

Journal of medical virology, 2018-01, Vol.90 (1), p.109-119

2018

Volltextzugriff (PDF)

Discovery of pyrido[2,3-d]pyrimidine-based inhibitors of HCV NS5A

Bioorganic & medicinal chemistry letters, 2013-06, Vol.23 (12), p.3627-3630

2013

Volltextzugriff (PDF)

Correction to: Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection

Journal of gastroenterology, 2018-05, Vol.53 (5), p.689-689

2018

Volltextzugriff (PDF)

Novel Hepatitis C virus replicon inhibitors: Synthesis and structure–activity relationships of fused pyrimidine derivatives

Bioorganic & medicinal chemistry letters, 2012-03, Vol.22 (6), p.2212-2215

2012

Volltextzugriff (PDF)

In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir

Antimicrobial agents and chemotherapy, 2017-05, Vol.61 (5)

2017

Volltextzugriff (PDF)

Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial

JAMA : the journal of the American Medical Association, 2015-03, Vol.313 (12), p.1223

2015

Volltextzugriff (PDF)

In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A

Antimicrobial agents and chemotherapy, 2015-02, Vol.59 (2), p.979-987

2015

Volltextzugriff (PDF)

In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450

Antimicrobial agents and chemotherapy, 2015-02, Vol.59 (2), p.988-997

2015

Volltextzugriff (PDF)

Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials

Antimicrobial agents and chemotherapy, 2018-10, Vol.62 (10)

2018

Volltextzugriff (PDF)

Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir/ritonavir

Antimicrobial agents and chemotherapy, 2015-11, Vol.59 (11), p.6807-6815

2015

Volltextzugriff (PDF)

Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir

Antimicrobial agents and chemotherapy, 2016-02, Vol.60 (2), p.1106-1113

2016

Volltextzugriff (PDF)

A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1

Journal of hepatology, 2013-07, Vol.59 (1), p.18-23

2013

Volltextzugriff (PDF)

Identification of Two Flavivirus-Like Genomes in the GB Hepatitis Agent

Proceedings of the National Academy of Sciences - PNAS, 1995-04, Vol.92 (8), p.3401-3405

1995

Volltextzugriff (PDF)

Identification of antigenic regions in the GB hepatitis viruses GBV-A, GBV-B, and GBV-C

Journal of medical virology, 1996-04, Vol.48 (4), p.329-338

1996

Volltextzugriff (PDF)

Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection

The Journal of infection, 2015-02, Vol.70 (2), p.197-205

2015

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Aktive Filter

KollektionTaylor & Francis

ThemaHepatitis C Virus

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(29)

Publikationsform

Artikel
(30)

Sprache

Englisch
(30)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(27)
Science & Technology
(27)
Humans
(24)
Hepacivirus - Genetics
(17)
Antiviral Agents
(15)
Genotype
(15)
Hepacivirus - Drug Effects
(15)
Pharmacology & Pharmacy
(15)
Hepatitis C
(11)
Microbiology
(11)
Antiviral Agents - Therapeutic Use
(10)
Female
(10)
Hepatitis C, Chronic - Drug Therapy
(10)
Male
(10)
Middle Aged
(10)
Biological And Medical Sciences
(9)
Drug Therapy, Combination
(9)
Viral Nonstructural Proteins - Antagonists & Inhibitors
(9)
Hepatitis
(8)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Hepatitis C virus drug resistance–associated substitutions: State of the art summary

An Interferon-free Antiviral Regimen for HCV after Liver Transplantation

Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection

Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis

Randomized trial of interferon‐ and ribavirin‐free ombitasvir/paritaprevir/ritonavir in treatment‐experienced hepatitis C virus–infected patients

Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b–infected Japanese patients with or without cirrhosis

Mutations Conferring Resistance to a Potent Hepatitis C Virus Serine Protease Inhibitor In Vitro

Ombitasvir/paritaprevir/ritonavir plus ribavirin for 24 weeks in patients with HCV GT4 and compensated cirrhosis (AGATE‐I Part II)

Evolution of Resistant M414T Mutants among Hepatitis C Virus Replicon Cells Treated with Polymerase Inhibitor A-782759

Activity of a Potent Hepatitis C Virus Polymerase Inhibitor in the Chimpanzee Model

Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir

Discovery of pyrido[2,3-d]pyrimidine-based inhibitors of HCV NS5A

Correction to: Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection

Novel Hepatitis C virus replicon inhibitors: Synthesis and structure–activity relationships of fused pyrimidine derivatives

In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir

Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial

In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A

In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450

Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials

Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir/ritonavir

Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir

A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1

Identification of Two Flavivirus-Like Genomes in the GB Hepatitis Agent

Identification of antigenic regions in the GB hepatitis viruses GBV-A, GBV-B, and GBV-C

Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection

Aktive Filter

Suchergebnisse filtern